Market Growth

AstraZeneca H1 Revenue Jumps 11% as It Pledges $50 Billion U.S. Expansion

Robust double-digit profit growth spurred a reassessment of a U.S. primary listing to strengthen its presence in the world’s largest biopharmaceutical market.